SG11201402032RA - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentInfo
- Publication number
- SG11201402032RA SG11201402032RA SG11201402032RA SG11201402032RA SG11201402032RA SG 11201402032R A SG11201402032R A SG 11201402032RA SG 11201402032R A SG11201402032R A SG 11201402032RA SG 11201402032R A SG11201402032R A SG 11201402032RA SG 11201402032R A SG11201402032R A SG 11201402032RA
- Authority
- SG
- Singapore
- Prior art keywords
- halofenate
- urate
- gout
- patients
- methods
- Prior art date
Links
- BJBCSGQLZQGGIQ-UHFFFAOYSA-N 2-acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)OCCNC(=O)C)OC1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-UHFFFAOYSA-N 0.000 title 1
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229950000958 halofenate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059394 WO2013066349A1 (fr) | 2011-11-04 | 2011-11-04 | Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402032RA true SG11201402032RA (en) | 2014-09-26 |
Family
ID=48192533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402032RA SG11201402032RA (en) | 2011-11-04 | 2011-11-04 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2773336A4 (fr) |
| JP (1) | JP6202633B2 (fr) |
| KR (1) | KR20140121383A (fr) |
| CN (2) | CN109908124A (fr) |
| AU (1) | AU2011380507B2 (fr) |
| CA (1) | CA2859686C (fr) |
| CL (1) | CL2014001155A1 (fr) |
| IL (1) | IL232386A0 (fr) |
| MX (1) | MX357507B (fr) |
| NZ (1) | NZ624708A (fr) |
| SG (1) | SG11201402032RA (fr) |
| WO (1) | WO2013066349A1 (fr) |
| ZA (1) | ZA201403575B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836209A4 (fr) * | 2012-04-13 | 2015-11-25 | Cymabay Therapeutics Inc | Méthode de traitement de l'hyperuricémie, faisant appel à l'halofénate ou à l'acide halofénique et à un agent anti-inflammatoire, chez les patients souffrant de goutte |
| JP6368756B2 (ja) * | 2016-10-20 | 2018-08-01 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
| CN108014108A (zh) * | 2016-11-03 | 2018-05-11 | 江苏万邦生化医药股份有限公司 | lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用 |
| US11446317B2 (en) | 2017-10-26 | 2022-09-20 | Otsuka Pharmaceutical Co., Ltd. | Inositol phosphate-containing composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| WO2011032175A1 (fr) * | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Formulations combinées de tranilast et d'allopurinol et procédés associées à celles-ci |
-
2011
- 2011-11-04 EP EP11875114.8A patent/EP2773336A4/fr not_active Withdrawn
- 2011-11-04 KR KR1020147015169A patent/KR20140121383A/ko active IP Right Grant
- 2011-11-04 MX MX2014005400A patent/MX357507B/es active IP Right Grant
- 2011-11-04 AU AU2011380507A patent/AU2011380507B2/en not_active Ceased
- 2011-11-04 CN CN201910004813.0A patent/CN109908124A/zh active Pending
- 2011-11-04 SG SG11201402032RA patent/SG11201402032RA/en unknown
- 2011-11-04 CA CA2859686A patent/CA2859686C/fr not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059394 patent/WO2013066349A1/fr active Application Filing
- 2011-11-04 JP JP2014541011A patent/JP6202633B2/ja not_active Expired - Fee Related
- 2011-11-04 NZ NZ624708A patent/NZ624708A/en not_active IP Right Cessation
- 2011-11-04 CN CN201180076191.4A patent/CN104066427A/zh active Pending
-
2014
- 2014-04-30 IL IL232386A patent/IL232386A0/en unknown
- 2014-05-02 CL CL2014001155A patent/CL2014001155A1/es unknown
- 2014-05-16 ZA ZA2014/03575A patent/ZA201403575B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201403575B (en) | 2015-11-25 |
| EP2773336A4 (fr) | 2015-06-03 |
| CN104066427A (zh) | 2014-09-24 |
| EP2773336A1 (fr) | 2014-09-10 |
| MX2014005400A (es) | 2015-02-12 |
| CA2859686C (fr) | 2018-09-11 |
| JP6202633B2 (ja) | 2017-09-27 |
| CL2014001155A1 (es) | 2015-01-16 |
| JP2014532758A (ja) | 2014-12-08 |
| MX357507B (es) | 2018-07-12 |
| NZ624708A (en) | 2015-11-27 |
| KR20140121383A (ko) | 2014-10-15 |
| AU2011380507B2 (en) | 2017-06-15 |
| CA2859686A1 (fr) | 2013-05-10 |
| IL232386A0 (en) | 2014-06-30 |
| CN109908124A (zh) | 2019-06-21 |
| WO2013066349A1 (fr) | 2013-05-10 |
| AU2011380507A1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180780T1 (hr) | Liječenje gihta i hiperurikemije | |
| EP2716669A4 (fr) | Procédé de modification de surface et corps élastique présentant une surface modifiée | |
| EP2627331A4 (fr) | Méthodes de traitement de l'hyperuricemie et de maladies liées | |
| EP2788075A4 (fr) | Dispositif et procédé de réduction de l'impédance transthoracique d'un patient | |
| PT3257546T (pt) | Método de preparação de cateter urinário pronto a utilizar | |
| SG11201401811WA (en) | Method for preventing and/or treating insulin resistance | |
| AP2015008931A0 (en) | Benzothiazole compounds and their pharmaceutical use | |
| PT2663864T (pt) | Método de avaliação de imunodiversidade e seu uso | |
| ZA201307742B (en) | Method for manufacturing and utilizing ferritic-austenitic stainless steel | |
| EP2739352A4 (fr) | Procédé et appareil d'électrothérapie multimodal | |
| PT2717692T (pt) | Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas | |
| DK2750705T3 (en) | Methods for effectively and rapidly desensitizing allergic patients | |
| PL2413718T3 (pl) | Zastosowanie kwasu arachidonowego do zmniejszenia ryzyka insulinooporności w późniejszym życiu | |
| ZA201403575B (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| SG11201401272RA (en) | Method for manufacturing acrylic acid-based polymer and use for same | |
| IL232385A (en) | Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder | |
| HK1204913A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent | |
| EP2640376A4 (fr) | Dérivés d'acide caféique et leur utilisation dans l'amélioration de la viabilité des cellules neuronales | |
| SG10201609202PA (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| EP2720703A4 (fr) | Procédés d'accroissement de la sensibilité à l'insuline et méthodes de traitement du diabète | |
| EP2773261A4 (fr) | Manomètre s'utilisant pour tester la région rachidienne et procédé correspondant | |
| GB201003894D0 (en) | Inhibitors of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome | |
| EP2548935A4 (fr) | Agent de désulfuration et son procédé de fabrication | |
| GB201008519D0 (en) | Method and apparatus for restricting ectoparasite infection in fish within a fish pen | |
| EP2768536A4 (fr) | Méthode de traitement des diabètes de type i et de type ii |